This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. AbbVie has bought a psychedelic compound from a little ...

Elaine Chen covers biotech, co-writes The Readout newsletter, and co-hosts STAT’s weekly biotech podcast, The Readout Loud. You can reach Elaine on Signal at elaineywchen.70. AbbVie on Monday said it ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. AbbVie plans to buy Gilgamesh Pharmaceuticals' lead ...

AbbVie has signed a definitive agreement to acquire Gilgamesh Pharmaceuticals' lead investigational candidate, bretisilocin, for up to $1.2bn, including an upfront payment and development milestones.

Oluwatokiloba, a freelance creative writer and editor living in Lagos, strikes a delicate balance between his academic studies at the University of Lagos and his love for writing. He is a voracious ...

-AbbVie said on Monday it would buy privately held Gilgamesh Pharmaceuticals' treatment for major depressive disorder in a deal worth up to $1.2 billion. This could help bolster AbbVie's portfolio of ...